학술논문
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study
Document Type
Article
Author
Ascierto, Paolo A ; Stroyakovskiy, Daniil; Gogas, Helen; Robert, Caroline; Lewis, Karl; Protsenko, Svetlana; Pereira, Rodrigo P; Eigentler, Thomas; Rutkowski, Piotr; Demidov, Lev; Zhukova, Natalia; Schachter, Jacob; Yan, Yibing; Caro, Ivor; Hertig, Christian; Xue, Cloris; Kusters, Lieke; McArthur, Grant A ; Gutzmer, Ralf
Source
In The Lancet Oncology January 2023 24(1):33-44
Subject
Language
ISSN
1470-2045